New trial aims to match AML patients with best drug combo

NCT ID NCT06635681

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding venetoclax to standard intensive chemotherapy improves outcomes for adults with acute myeloid leukemia (AML). The study will enroll 380 patients aged 14 to 60 to see which genetic subtypes benefit most. Researchers hope to personalize treatment based on genetic markers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Venetoclax combined with daunorubicin, cytarabine, and azacitidine
What this could lead to: If successful, this could identify which genetic types of AML respond best to adding venetoclax to standard chemo, leading to more personalized treatment.
What could go wrong: This is a phase 2 single-arm trial, so results are preliminary and may not confirm benefit. Side effects from intensive chemo plus venetoclax could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOGENOUS LEUKEMIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML (ACUTE MYELOGENOUS LEUKEMIA)

Contacts and locations

Locations

Blood Diseases Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.